Gentium plunges on concerns by safety board over study
Gentium S.p.A. (Nasdaq:GENT) shares are plunging 27% after the biopharmaceutical company said a safety board had worries about the results of its late-stage trial of a treatment for severe veno-occlusive disease. The firm also received a downgrade by Rodman & Renshaw to “Market Perform” from “Outperform.”
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
